[Infostock Daily=Reporter Lee Ji-sun] Celltrion's Covid-19 antibody treatment was recommended for a second expert advisory review before final approval of it.
The Ministry of Food and Drug Safety said at an advisory meeting held at 2 p.m. on the 27th that the Central Pharmacist Review Committee recommended Celltrion's permission for Covid-19 antibody treatment on the premise of Phase III clinical trials.
The central weakness is the second step in the 'triple advisory of external experts' to review the permission of Covid-19 treatments and vaccines.
However, contrary to the opinion of the last verification advisory group, it was difficult to conclude the clinical effect of the drug administration on 'mild patients.' Therefore, it was recommended that the medication be administered to patients with 'medium symptoms' and 'high-risk group with mild symptoms'.
Reporter Lee Ji-sun stockmk2020@gmail.com
